Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Kendall Law Group, a national securities litigation firm is investigating Facet Biotech Corporation (NASDAQ: FACT) for shareholders in connection to the proposed sale of the Company to Abbott Laboratories. If you are a FACT shareholder and would like additional information about your rights, you are encouraged to contact the Kendall Law Group at 877-744-3728 or by email at hlindley@kendalllawgroup.com.

On March 9, 2010, Facet and Abbott announced that they had entered into an agreement for Facet to be acquired by Abbott in a $450 million transaction expected to close in the second quarter of 2010. According to the agreement, shareholders will receive $27.00 in cash per FACT share owned. The firm is investigating whether fair process was used in shopping the Company prior to entering into the agreement, and whether the Board of Directors breached their fiduciary duties by not seeking a deal that would provide better value of the Company.

Kendall Law Group has been counsel in many merger and acquisition cases nationwide, including some of the largest transactions in the United States. The firm is founded by a former federal judge, and includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. Protect your rights as a FACT shareholder by calling the firm.

Facet Biotech (MM) (NASDAQ:FACT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024